Back to Agenda
[S09] What is “Shared Value” Created by Collaboration Among Industry, Academia, Government and Individuals of Current and Future Generations - Going Forward to New Era of Innovation
Session Chair(s)
Minori Niso
Senior Director, Japan Strategy & Marketing
Parexel, Japan
With a decrease in the success probability of drug/device development, an idea of “open innovation” has been spreading out with a transition from a classical methodology to a brand new one by crossing organizational boundaries. In this session, with a theme of “Win-win relationship by industry, government and academia”, an example of government effort to connect industry and academia, and an idea of “creating shared value (CSV)” by the industry to achieve a synergism between economic benefit and social value creation will be reviewed. From academia, an example of a cross-cultural collaboration will be explained. Through these discussions, let us think about “What is new innovation toward the common goal by industry, government and academia?” for the better collaboration for our future.
Speaker(s)
Measures by AMED for Drug Discovery and Development Through all Japan Partnership
Tomonori Shiokawa
Japan Agency for Medical Research and Development (AMED), Japan
Manager, Department of Innovative Drug Discovery and Development
Keiichi Fujiwara, MD, PhD
Saitama Medical University International Medical Center, Japan
Professor, Department of Gynecologic Oncology Chief
Overview of SDGs, CSV (Creating Shared Value) and Collective Impact
Ryota Inaba
Flexas Z inc., Japan
General Manager
Have an account?